Lower SLC7A2 expression is associated with enhanced multidrug resistance, less immune infiltrates and worse prognosis of NSCLC

Amino Acid Solute Carrier Transporters in Inflammation and Autoimmunity

(2022) Linlin Sheng et al.   DRUG METABOLISM AND DISPOSITION

Hypothalamic AMPK as a possible target for energy balance-related diseases

(2022) Miguel López   TRENDS IN PHARMACOLOGICAL SCIENCES

Crosstalk between tumor-associated macrophages and tumor cells promotes chemoresistance via CXCL5/PI3K/AKT/mTOR pathway in gastric cancer

(2022) Pengfei Su et al.   Cancer Cell International

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

SLC7A7 is a prognostic biomarker correlated with immune infiltrates in non-small cell lung cancer

(2021) Wumin Dai et al.   Cancer Cell International

Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer

(2021) S. Sugawara et al.   ANNALS OF ONCOLOGY

Lung cancer

(2021) Alesha A Thai et al.   LANCET

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

(2021) Yunpeng Yang et al.   LANCET ONCOLOGY

SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells

(2021) Suhong Xia et al.   Cell Death & Disease

Tumor Targeted Polymer Nanoparticles Co-loaded with Docetaxel and siCCAT2 for Combination Therapy of Lung Cancer

(2021) Dayong Xiao et al.   JOURNAL OF DRUG TARGETING

New Therapeutic Strategy for Overcoming Multidrug Resistance in Cancer Cells with Pyrazolo[3,4-d]pyrimidine Tyrosine Kinase Inhibitors

(2021) Ana Podolski-Renić et al.   Cancers

AMP-activated protein kinase re-sensitizes A549 to paclitaxel via up-regulating solute carrier organic anion transporter family member 1B3 expression

(2021) Shanshan Jiang et al.   CELLULAR SIGNALLING

The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer

(2020) Lei Zhang et al.   Molecular Cancer

TIMER2.0 for analysis of tumor-infiltrating immune cells

(2020) Taiwen Li et al.   NUCLEIC ACIDS RESEARCH

SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer

(2020) Tianshui Sun et al.   Aging-US

TNF‐α and IL‐1β sensitize human MSC for IFN‐γ signaling and enhance neutrophil recruitment

(2020) Alexander Hackel et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

LKB1/AMPK Pathway and Drug Response in Cancer: A Therapeutic Perspective

(2019) Francesco Ciccarese et al.   Oxidative Medicine and Cellular Longevity

Loss of solute carrier family 7 member 2 exacerbates inflammation-associated colon tumorigenesis

(2018) Lori A. Coburn et al.   ONCOGENE

Titanium surface characteristics, including topography and wettability, alter macrophage activation

(2016) Kelly M. Hotchkiss et al.   Acta Biomaterialia

Clinical significance and role of LKB1 in gastric cancer

(2015) SHANSHAN JIANG et al.   Molecular Medicine Reports

Solute carrier protein family may involve in radiation-induced radioresistance of non-small cell lung cancer

(2011) Li Xie et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY